93 related articles for article (PubMed ID: 3291770)
21. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma.
Mach JP; Chatal JF; Lumbroso JD; Buchegger F; Forni M; Ritschard J; Berche C; Douillard JY; Carrel S; Herlyn M
Cancer Res; 1983 Nov; 43(11):5593-600. PubMed ID: 6616486
[TBL] [Abstract][Full Text] [Related]
22. Lymphoscintigraphy of human colorectal carcinoma metastases in athymic mice by use of radioiodinated B72.3 monoclonal antibody.
Shah SA; Gallagher BM; Sands H
J Natl Cancer Inst; 1987 Jun; 78(6):1069-77. PubMed ID: 3473248
[TBL] [Abstract][Full Text] [Related]
23. Applications of immunocytochemistry to clinical cytology.
Johnston WW; Szpak CA; Thor A; Simpson JF; Schlom J
Cancer Invest; 1987; 5(6):593-611. PubMed ID: 3327572
[TBL] [Abstract][Full Text] [Related]
24. A CDR-grafted (humanized) domain-deleted antitumor antibody.
Slavin-Chiorini DC; Kashmiri SV; Lee HS; Milenic DE; Poole DJ; Bernon E; Schlom J; Hand PH
Cancer Biother Radiopharm; 1997 Oct; 12(5):305-16. PubMed ID: 10851481
[TBL] [Abstract][Full Text] [Related]
25. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients.
Gallinger S; Reilly RM; Kirsh JC; Odze RD; Schmocker BJ; Hay K; Polihronis J; Damani MT; Shpitz B; Stern HS
Cancer Res; 1993 Jan; 53(2):271-8. PubMed ID: 8417820
[TBL] [Abstract][Full Text] [Related]
26. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy.
Schlom J; Molinolo A; Simpson JF; Siler K; Roselli M; Hinkle G; Houchens DP; Colcher D
J Natl Cancer Inst; 1990 May; 82(9):763-71. PubMed ID: 2182892
[TBL] [Abstract][Full Text] [Related]
27. Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients.
Roselli M; Hitchcock CL; Molinolo A; Milenic DE; Colcher D; Martin EW; Hinkle GH; Schlom J
Anticancer Res; 1995; 15(3):975-84. PubMed ID: 7645989
[TBL] [Abstract][Full Text] [Related]
28. Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72.3.
Johnston WW; Szpak CA; Thor A; Schlom J
Cancer Res; 1986 Dec; 46(12 Pt 1):6462-70. PubMed ID: 3022920
[TBL] [Abstract][Full Text] [Related]
29. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies.
Colcher D; Minelli MF; Roselli M; Muraro R; Simpson-Milenic D; Schlom J
Cancer Res; 1988 Aug; 48(16):4597-603. PubMed ID: 3396011
[TBL] [Abstract][Full Text] [Related]
30. Comparative biodistribution and antibody-dependent cellular cytotoxicity of native and heavy chain chimeric antibody.
Gallinger S; Papa MZ; Reilly RM; Xiang J; Kirsh JC; Mullen JB; Stern HS; Hozumi N; Roder JC
Mol Biother; 1991 Dec; 3(4):197-203. PubMed ID: 1768371
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model.
Burvenich I; Schoonooghe S; Cornelissen B; Blanckaert P; Coene E; Cuvelier C; Mertens N; Slegers G
Clin Cancer Res; 2005 Oct; 11(20):7288-96. PubMed ID: 16243799
[TBL] [Abstract][Full Text] [Related]
32. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3.
Thor A; Ohuchi N; Szpak CA; Johnston WW; Schlom J
Cancer Res; 1986 Jun; 46(6):3118-24. PubMed ID: 3516392
[TBL] [Abstract][Full Text] [Related]
33. Radioimmunoscintigraphy of human colon cancer xenografts in mice with radioiodinated monoclonal antibody B72.3.
Keenan AM; Colcher D; Larson SM; Schlom J
J Nucl Med; 1984 Nov; 25(11):1197-203. PubMed ID: 6333494
[TBL] [Abstract][Full Text] [Related]
34. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer.
Colcher D; Milenic DE; Ferroni P; Carrasquillo JA; Reynolds JC; Roselli M; Larson SM; Schlom J
J Nucl Med; 1990 Jul; 31(7):1133-42. PubMed ID: 2362192
[TBL] [Abstract][Full Text] [Related]
35. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions.
Johnston WW; Szpak CA; Lottich SC; Thor A; Schlom J
Cancer Res; 1985 Apr; 45(4):1894-900. PubMed ID: 3884146
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibody B72.3 reactivity with human endometrium: a study of normal and malignant tissues.
Thor A; Viglione MJ; Muraro R; Ohuchi N; Schlom J; Gorstein F
Int J Gynecol Pathol; 1987; 6(3):235-47. PubMed ID: 3429107
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
38. Expression of TAG-72 in normal colon, transitional mucosa, and colon cancer.
Xu M; Real FX; Welt S; Schüssler MH; Oettgen HF; Old LJ
Int J Cancer; 1989 Dec; 44(6):985-9. PubMed ID: 2481651
[TBL] [Abstract][Full Text] [Related]
39. Differences in biodistribution of indium-111-and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer.
Yokoyama K; Carrasquillo JA; Chang AE; Colcher D; Roselli M; Sugarbaker P; Sindelar W; Reynolds JC; Perentesis P; Gansow OA
J Nucl Med; 1989 Mar; 30(3):320-7. PubMed ID: 2738661
[TBL] [Abstract][Full Text] [Related]
40. Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant.
Hand PH; Calvo B; Milenic D; Yokota T; Finch M; Snoy P; Garmestani K; Gansow O; Schlom J; Kashmiri SV
Cancer Immunol Immunother; 1992; 35(3):165-74. PubMed ID: 1638552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
